Proper CMC Submission -API. Ramnarayan Randad, Ph.D. DMF Review Staff/OGD June 4, 2014 GPhA/FDA Bethesda, MD

Size: px
Start display at page:

Download "Proper CMC Submission -API. Ramnarayan Randad, Ph.D. DMF Review Staff/OGD June 4, 2014 GPhA/FDA Bethesda, MD"

Transcription

1 Proper CMC Submission -API Ramnarayan Randad, Ph.D. DMF Review Staff/OGD June 4, 2014 GPhA/FDA Bethesda, MD 1

2 Type II Drug Master Files (DMFs) and GDUFA Generic Drug User Fee Amendments (GDUFA) July 9, 2012 (FDASIA PDUFA, GDUFA, BsUFA). Type II DMF -one-time user fee Pass Completeness Assessment Available for Reference -Oct 2014, ww.fda.gov/gdufa DMF team pilot 2010 Affects ANDA submission Risk of causing an RTR ANDA applicant is notified ( ) of the DMF status 2

3 Completeness Assessment (CA) GDUFA requires Type II API DMFs to undergo an initial CA to ensure that the DMF is complete. Agency Guidance (10/1/2012), that include recommendation on information that should be included in the DMF. CA checklist follows CTD format: Has 62 questions DMFs that pass initial CA are published on the FDA s public Web site as available for reference ( 3

4 Format of the Checklist Administrative/General Information (question 1-11) 2.3.S QOS (question 12) 3.2.S.1 General Information (question 13-15) 3.2.S.2 Manufacture (question 16-36) 3.2.S.3 Characterization (question 37-40) 3.2.S.4 Control of Drug Substance (question 41-45) 3.2.S.5 Reference Standards or Materials (question 46-51) 3.2.S.6 Container Closure System (question 52-54) 3.2.S.7 Stability (question 55-58) 3.2 R Regional info (question 59-61) 4

5 CA Review Process DMF holder Actions DMF holder pays the DMF fee DMF holder sends notification to hhs.gov DMF holder submits amendment ANDA applicant who references this DMF FDA Actions Generate CA queue and prioritize. Issue Incomplete letter to DMF holder.* No *Notification of Incomplete status is sent to ANDA applicant if the DMF has been referenced by a submitted ANDA under filing review. Is DMF Eligible for Admin CA? No Assign to reviewer for full CA Is DMF Complete? Yes DMFs listed as available for reference on FDA website Yes 5

6 How is the Generic Industry doing with CAs? Overall Industry is adapting very well. Some metrics: DMFs for Full CA complete on the first cycle: 17% DMFs for Full CA complete by the second cycle: 88% Average response time (first cycle): 45 days CTD format and Electronic- CTD submissions greatly facilitate the process efficiency 6

7 Clarifications on DMF [Common Queries] API is a substance or a mixture when the substance is unstable or cannot be transported on its own. DMF for a mixture (e.g. API plus an excipient) can qualify as the API under GDUFA. We ask that a justification be submitted to the DMF when this claim is made. Note that these situations also have important facility fee implications. The CA requires that a DMF be for a single API produced by a single manufacturing process. 7

8 Clarifications (continued) DMF should be limited to one process although multiple manufacturing sites for a single drug process is permitted. Certain process alternatives/changes may be permissible with sufficient supportive information provided. e.g.: Validated reprocess/rework procedures Micronization leading to different particle sizes Addition of a stabilizing antioxidant for stability purpose Alternate crystallization procedure to produce a different polymorph Minor process variation that is the same chemical transformation with little risk to the impurity profile Factors which are indicative of a second process Significant process alternation resulting in different impurity profile and requiring different control strategy Different starting materials Different Intermediates 8

9 Clarifications (continued) What is the stability data requirement to pass the CA? Do the provisions of the new stability guidance apply? The guidance requirements apply to the full scientific review. To pass the CA the firm needs to demonstrate that stability studies have started (i.e. one batch with a time point beyond initial). 9

10 Policy Change for FY 2015 DMF must be Available for Reference at the time of ANDA submission or the ANDA will be Refuse to Receive For FY 2013 and 2014 this was not the case DMF holders had the entire ANDA filing window to become Available for Reference Firm s will need to coordinate DMF fee payment and ANDA submission to allow the DMF to pass the CA (we recommend 6 months) 10

11 Average time to CA Completion by Payment Month (Full CA, first cycle) Backlog > 400 Initial Bolus Cleared Backlog : 78 Backlog > Large influence of the bolus on timelines Impact was partially muted do to hiring September 2013 bolus has been cleared so another downward trend is expected # of Paid DMFs Avg Days of 1st CA Review

12 Avoid an RTR due to the DMF-Suggestions Make sure the DMF is on the Available for Reference list prior to ANDA submission Communicate with the DMF holder so they know the ANDA submission timeframe. Pay the DMF fee six-months in advance of the planned ANDA submission date This will allow sufficient time for two cycles of CA review (if needed) Submit a high-quality DMF (preferably in ectd format) 12

13 Avoid an RTR due to the DMF- Be Proactive! Know if the DMF is eligible for an administrative CA Make sure the choice of starting materials is appropriately justified For older DMFs, know whether a complete update needs to be submitte and submit ahead of payment! Make sure FDA has the current contact information (fax number) Respond to Incomplete letters as quickly as possible (30 days or less is ideal) Provide notification of amendment as instructed on the fax cover sheet! Contact us with CA status requests if the DMF is not on the list or you have not received a DMF Incomplete 13 communication (DMFOGD@FDA.HHS.GOV)

14 Resources from Oct 1, Growth in DMF Staff Since Oct 1, 2012 Oct-12 Dec-12 Feb-13 Apr-13 Jun-13 Aug-13 Oct-13 Dec-13 Feb-14 Apr-14 Large increase in resources since Oct 1, GDUFA hires in FY GDUFA hires in 2014 Total review Staff of 61 by end of 2014 Increased capability to cope with large and variable workload. Will result in much lower and predictable CA timelines

15 Thank you 15

Status Update on the Review of DMFs

Status Update on the Review of DMFs Status Update on the Review of DMFs Presented by Dave Skanchy, Ph.D. Director DMF Review Staff GPhA/FDA CMC Workshop June 4, 2013 1 Outline Changes to the DMF Review Staff: Update on GDUFA hiring and the

More information

GDUFA II User Fees. Update on Implementation

GDUFA II User Fees. Update on Implementation GDUFA II User Fees Update on Implementation Donal Parks, Director Division of User Fee Management and Budget Formulation OM CDER US FDA November 8, 2017 Outline Refresher on GDUFA II fee structure What

More information

Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry

Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

GDUFA: 2 ½ years later Impact & Importance

GDUFA: 2 ½ years later Impact & Importance GDUFA: 2 ½ years later Impact & Importance Georgia Hizon Manager, Regulatory Publications Fresenius Kabi USA, LLC Disclaimer The views and opinions expressed in the following PowerPoint slides are those

More information

ANDA Filing and Refuse to Receive Issues. Johnny Young, M.A.L.A.

ANDA Filing and Refuse to Receive Issues. Johnny Young, M.A.L.A. ANDA Filing and Refuse to Receive Issues Johnny Young, M.A.L.A. 1 Statistics 2 497 ANDAs Refused-for-Receipt between CYs 2009-2012: - 12% (2009) - 18% (2010) - 15.5% (2011) - 9.4% (2012) 3 For 2012, 100

More information

ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry

ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments

More information

Guidance for Industry ANDA Submissions Refuse-to-Receive Standards

Guidance for Industry ANDA Submissions Refuse-to-Receive Standards Guidance for Industry ANDA Submissions Refuse-to-Receive Standards DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document

More information

Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public Hearing;

Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public Hearing; 4160-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 15 [Docket No. FDA-2013-N-0402] Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public

More information

OFFICE OF PHARMACEUTICAL SCIENCES. COVER FORM FOR THE TECHNICAL REVIEW OF DRUG MASTER FILES (DMFs) CONTENTS

OFFICE OF PHARMACEUTICAL SCIENCES. COVER FORM FOR THE TECHNICAL REVIEW OF DRUG MASTER FILES (DMFs) CONTENTS MANUAL OF POLICIES AND PROCEDURES CENTER FOR DRUG EVALUATION AND RESEARCH MAPP 5015.3 OFFICE OF PHARMACEUTICAL SCIENCES COVER FORM FOR THE TECHNICAL REVIEW OF DRUG MASTER FILES (DMFs) CONTENTS PURPOSE

More information

510(k) submissions. Getting US FDA clearance for your device: Improving

510(k) submissions. Getting US FDA clearance for your device: Improving Getting US FDA clearance for your device: Improving 510(k) submissions Audrey Swearingen, RAC Director, Regulatory Affairs Telephone: +1 512.222.0263 Email: aswearingen@emergogroup.com Download this white

More information

Cancer Immunotherapy Pilot Program/ Patents 4 Patients. USPTO BCP Customer Partnership Meeting Alexandria, VA August 2, 2017

Cancer Immunotherapy Pilot Program/ Patents 4 Patients. USPTO BCP Customer Partnership Meeting Alexandria, VA August 2, 2017 Cancer Immunotherapy Pilot Program/ Patents 4 Patients USPTO BCP Customer Partnership Meeting Alexandria, VA August 2, 2017 1 Cancer Immunotherapy Pilot Program/ Patents 4 Patients The United States Patent

More information

Texas Vendor Drug Program Specialty Drug List Process. February 2019

Texas Vendor Drug Program Specialty Drug List Process. February 2019 Texas Vendor Drug Program Specialty Drug List Process February 2019 Table of Contents Table of Contents...1 1 About the Specialty Drug List...2 1.1 Information for Pharmacies... 2 1.2 Information for Managed

More information

Office of Generic Drugs. April 14, 2010

Office of Generic Drugs. April 14, 2010 Considerations for PET ANDAs Office of Generic Drugs April 14, 2010 1 Agenda Office of Generic Drugs: background information RLDs and Suitability Petitions Submission requirements for an ANDA Approval

More information

Guideline on influenza vaccines submission and procedural requirements

Guideline on influenza vaccines submission and procedural requirements 1 2 3 October 2014 EMA/56793/2014 Human Medicines Research and Development Support 4 5 6 Guideline on influenza vaccines submission and procedural requirements Regulatory and procedural requirements module

More information

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: SOP number: SOP category: Version number: 03 Version date: 19 December 2016 Effective date: 19 January 2017 Revision due date: 19 January 2020 NEWCASTLE CLINICAL TRIALS UNIT STANDARD

More information

Autism Funding Programs

Autism Funding Programs Autism Funding Programs A Guide to Invoice Payment Forms Why is Autism Funding Provided? The primary intent of Autism Funding is to assist families with the cost of purchasing autism intervention that

More information

Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044

Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044 DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 090783 Food and Drug Administration Silver Spring, MD 20993 Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs

More information

CLIENT PROCEDURE FOR ANNUAL APPROVAL OF SHIP REPAIR COMPANIES

CLIENT PROCEDURE FOR ANNUAL APPROVAL OF SHIP REPAIR COMPANIES CLIENT PROCEDURE FOR ANNUAL APPROVAL OF SHIP REPAIR COMPANIES 1.0 PURPOSE Safe work environment is essential for performing all kinds of ship repair operations. In this regard and to enable safe and smooth

More information

MEAT CONTENT CALCULATION

MEAT CONTENT CALCULATION MEAT CONTENT CALCULATION Introduction Amendments to the European Labelling Directive have resulted in the need to harmonise the definition of meat across Europe. This new definition attempts to ensure

More information

Get Instant Access to ebook Anda Checklist PDF at Our Huge Library ANDA CHECKLIST PDF. ==> Download: ANDA CHECKLIST PDF

Get Instant Access to ebook Anda Checklist PDF at Our Huge Library ANDA CHECKLIST PDF. ==> Download: ANDA CHECKLIST PDF ANDA CHECKLIST PDF ==> Download: ANDA CHECKLIST PDF ANDA CHECKLIST PDF - Are you searching for Anda Checklist Books? Now, you will be happy that at this time Anda Checklist PDF is available at our online

More information

Medical Necessity and the Retrospective Review Process

Medical Necessity and the Retrospective Review Process Medical Necessity and the Retrospective Review Process Medicaid Retrospective Therapy Review Medicaid contracted with QSource of Arkansas to perform post-payment audits Random quarterly selection across

More information

Guide to Interchangeable Medicines

Guide to Interchangeable Medicines Guide to Interchangeable Medicines AUT-G0115-6 01 JUNE 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS 1 BACKGROUND 3 1.1

More information

Overview of Regulatory Science of Food Contact Substances

Overview of Regulatory Science of Food Contact Substances Overview of Regulatory Science of Food Contact Substances Michael A. Adams, PhD Deputy Director, Office of Food Additive Safety FDA, Center for Food Safety and Applied Nutrition 5001 Campus Drive, College

More information

Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure

Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure 1 2 3 4 5 6 7 8 9 14 April 2010 EMA/CHMP/BWP/99698/2007 Rev. 1 Committee for Medicinal Products for Human Use (CHMP) Procedural advice on the submission of variations for annual update of human influenza

More information

Criteria and Application for Men

Criteria and Application for Men Criteria and Application for Men Return completed form via fax or email to LIVESTRONG Foundation attn LIVESTRONG Fertility Fax 512.309.5515 email Cancer.Navigation@LIVESTRONG.org Made possible by participating

More information

Part D PDE Data and the Opioid Epidemic

Part D PDE Data and the Opioid Epidemic Part D PDE Data and the Opioid Epidemic State Data Resource Center Acumen, LLC August 30, 2017 3:30-4:30pm ET Outline Background Information on Opioid Use Helpful Part D Elements for Analysis How to Perform

More information

Taking Part B Therapy Beyond the $3,700 Threshold New Manual Medical Review Process Effective date October 1, 2012

Taking Part B Therapy Beyond the $3,700 Threshold New Manual Medical Review Process Effective date October 1, 2012 Taking Part B Therapy Beyond the $3,700 Threshold New Manual Medical Review Process Effective date October 1, 2012 Presented by: Leigh Ann Frick, PT, MBA Vice President of Clinical Services Heritage Healthcare

More information

Guideline on the Regulation of Therapeutic Products in New Zealand

Guideline on the Regulation of Therapeutic Products in New Zealand Guideline on the Regulation of Therapeutic Products in New Zealand Part 10: Requirements for information for prescribers and consumers Edition 7.0 January 2016 Section 1: Legislation Section summary This

More information

MEDICINES CONTROL COUNCIL

MEDICINES CONTROL COUNCIL MEDICINES CONTROL COUNCIL GUIDELINES and FORMS TABLE OF CONTENTS 1 Guidelines and Forms 1.01 Index to Guidelines and Forms 2 Human Medicines 2.01 General information 2.02 Pharmaceutical and Analytical

More information

Section VII: HIV/AIDS & STD. MPR 1 Provide and/or refer clients for HIV and STD screening and treatment, regardless of client ability to pay.

Section VII: HIV/AIDS & STD. MPR 1 Provide and/or refer clients for HIV and STD screening and treatment, regardless of client ability to pay. All Minimum Program Requirements (MPRs) and Indicators listed below are required for the agency to meet in order to pass the HIV/AIDS and STD section of the Accreditation Review. Sources of authority:

More information

Research on the Administrative Rules of APIs, Pharmaceutical Excipients and Auxiliary Materials Master File. Translation version

Research on the Administrative Rules of APIs, Pharmaceutical Excipients and Auxiliary Materials Master File. Translation version Research on the Administrative Rules of APIs, Pharmaceutical Excipients and Auxiliary Materials Master File Division of Pharmaceuticals Department of Drug Registration Hou Renping Translation version Main

More information

2010 Sharing Hope Program for men

2010 Sharing Hope Program for men 2010 Sharing Hope Program for men Criteria and Application Made possible by participating sperm banks and fertility centers Program Overview Goal Cancer patients have little opportunity to save for the

More information

MHRA Pharmacovigilance Inspections: Prepare and Manage for Success

MHRA Pharmacovigilance Inspections: Prepare and Manage for Success MHRA Pharmacovigilance Inspections: Prepare and Manage for Success Created and Presented by Miranda Dollen Vice President, Pharmacovigilance & EEA QPPV Mapi 2016, All Rights Reserved 2 Prepare and Manage

More information

Consultant-led Referral to Treatment (RTT) waiting times collection timetable: outcome of consultation

Consultant-led Referral to Treatment (RTT) waiting times collection timetable: outcome of consultation Consultant-led Referral to Treatment (RTT) waiting times collection timetable: outcome of consultation Summary Between January and March 2014, NHS England consulted on a proposed change to the timetable

More information

McLean ebasis plus TM

McLean ebasis plus TM McLean ebasis plus TM Sample Hospital (0000) Report For Qtr HBIPS Core Measures McLean Hospital 115 Mill Street Belmont, MA 02478 1 2012 Department of Mental Health Services Evaluation Tel: 617-855-3797

More information

Inpatient Psychiatric Facility Quality Reporting (IPFQR) Program

Inpatient Psychiatric Facility Quality Reporting (IPFQR) Program FY 2017 IPPS Final Rule IPFQR Changes, APU Determination and Reconsideration Review Questions and Answers Moderator/Speaker: Evette Robinson, MPH Project Lead, IPFQR Inpatient Hospital Value, Incentives,

More information

CDER Compliance Update

CDER Compliance Update CDER Compliance Update Douglas Stearn, JD Deputy Director for Policy and Analysis FDA/CDER/Office of Compliance FDLI Enforcement, Litigation and Compliance Conference Washington, DC December 12, 2012 1

More information

Oncology Solutions Provider Training Program. Horizon NJ Health

Oncology Solutions Provider Training Program. Horizon NJ Health Oncology Solutions Provider Training Program Horizon NJ Health NIA Training Program NIA A Magellan Health Company 2 NIA Program Agenda Introduction to the Training Our Program 1. Authorization Process

More information

INFORMATION FOR RESEARCHERS REQUESTING DATA FROM THE NHVPR

INFORMATION FOR RESEARCHERS REQUESTING DATA FROM THE NHVPR INFORMATION FOR RESEARCHERS REQUESTING DATA FROM THE NHVPR What is the NHVPR? The National Human Papillomavirus Vaccination Program Register (NHVPR) is the Australian register which records HPV vaccine

More information

Preparing a US FDA Medical Device 510(K) Submission

Preparing a US FDA Medical Device 510(K) Submission Preparing a US FDA Medical Device 510(K) Submission If you want to introduce your medical device to the US market, you need to obtain clearance from the FDA. This clearance is obtained from the FDA via

More information

Parametric Release Regulatory Requirements. Terry E. Munson Technical Vice President PAREXEL International, LLC

Parametric Release Regulatory Requirements. Terry E. Munson Technical Vice President PAREXEL International, LLC Parametric Release Regulatory Requirements Terry E. Munson Technical Vice President History First application approved for parametric release in 1985 Formed the basis for the FDA Compliance Policy Guide

More information

USDA Demonstration Project for Non-Congregate Feeding for Outdoor Summer Meal Sites Experiencing Excessive Heat

USDA Demonstration Project for Non-Congregate Feeding for Outdoor Summer Meal Sites Experiencing Excessive Heat SUMMER FOOD SERVICE PROGRAM CLARIFICATION OF FEDERAL POLICY In Texas, organizations contracting directly with the (TDA) to operate nutrition programs federally funded through the United States Department

More information

Enhanced service specification Childhood seasonal influenza vaccination programme NHS England gateway reference: 01641

Enhanced service specification Childhood seasonal influenza vaccination programme NHS England gateway reference: 01641 Enhanced service specification Childhood seasonal influenza vaccination programme NHS England gateway reference: 01641 Introduction 1. All GMS practices are expected to provide essential and those additional

More information

Guideline on the processing of renewals in the centralised procedure

Guideline on the processing of renewals in the centralised procedure 14 July 2016 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation December 2000

More information

Procedure for Registration / Renewal of Third Party Hazmat/Industrial Tank Cleaning Contractors

Procedure for Registration / Renewal of Third Party Hazmat/Industrial Tank Cleaning Contractors Procedure for Registration / Renewal of Third Party Hazmat/Industrial Tank Cleaning Contractors 1. PURPOSE: The competency and integrity of the 3 rd party Hazmat/ Industrial Tank Cleaning contractors are

More information

The American College of Radiology Breast Ultrasound Accreditation Program: Frequently Asked Questions (Revised: July 31, 2017)

The American College of Radiology Breast Ultrasound Accreditation Program: Frequently Asked Questions (Revised: July 31, 2017) The American College of Radiology Breast Ultrasound Accreditation Program: Frequently Asked Questions (Revised: July 31, 2017) Table of Contents APPLICATION - GENERAL... 1 MOVED FACILITIES AND UNITS...

More information

Risk-Based CMC ANDA Review

Risk-Based CMC ANDA Review Risk-Based CMC ANDA Review Andre Raw*, PhD Director Division of Chemistry I FDA-CDER- Office of Generic Drugs andre.raw@fda.hhs.gov *This presentation reflects the views of the author and should not be

More information

Sport and Exercise Science Undergraduate Practicum Application Packet Instructions

Sport and Exercise Science Undergraduate Practicum Application Packet Instructions Sport and Exercise Science Undergraduate Practicum Application Packet Instructions Please read the ENTIRE instructions and information sheets carefully for complete directions and information before completing

More information

Feidhmeannacht na Seirbhíse Sláinte

Feidhmeannacht na Seirbhíse Sláinte Feidhmeannacht na Seirbhíse Sláinte Health Service Executive TITLE FORENAME SURNAME ADDRESS 1 ADDRESS 2 ADDRESS 3 COUNTY Feidhmeannacht na Seirbhíse Sláinte Seirbhís Aisíoca Príomhchúraim Bealach amach

More information

Harvard Pilgrim Spine Management Provider Training

Harvard Pilgrim Spine Management Provider Training Harvard Pilgrim Spine Management Provider Training NIA Training Program 2 NIA Program Agenda Our Program 1. Authorization Process 2. Other Program Components 3. Provider Tools and Contact Information RadMD

More information

Pre-Claim Review Demonstration for Home Health Services in IL. Implementation Workshop Series

Pre-Claim Review Demonstration for Home Health Services in IL. Implementation Workshop Series Pre-Claim Review Demonstration for Home Health Services in IL Implementation Workshop Series Disclaimer The information enclosed was current at the time i t was presented. Medicare policy changes frequently;

More information

RPL Form Diploma of Remedial Massage HLT50307

RPL Form Diploma of Remedial Massage HLT50307 Please read the information below and complete all sections of this form. RPL Form Diploma of Remedial Massage HLT50307 Recognition of Prior Learning (RPL) ACFB provides a simple process in gaining Recognition

More information

(In chronological order, provide work, volunteer, community service information after earning your initial dental degree)

(In chronological order, provide work, volunteer, community service information after earning your initial dental degree) NOTE For the Dental Curriculum Vitae (CV), provide information on your educational credentials and dental experience starting after your initial dental degree. Please classify your dental experience by

More information

Public Policy HCA Public Policy No

Public Policy HCA Public Policy No Public Policy HCA Public Policy No.11-2016 TO: FROM: RE: HCA HOSPICE PROVIDER MEMBERS PATRICK CONOLE, VICE PRESIDENT, FINANCE & MANAGEMENT UPDATES FROM NGS HOSPICE ADVISORY MEETING DATE: JUNE 10, 2016

More information

Update on CDER s Drug Development Tool Qualification Program

Update on CDER s Drug Development Tool Qualification Program Update on CDER s Drug Development Tool Qualification Program ShaAvhree Buckman-Garner, M.D., Ph.D. Director Office of Translational Sciences Center for Drug Evaluation and Research U.S. Food and Drug Administration

More information

New Drugs Division. Frequently Asked Questions (FAQs) on Approval of new Phytopharmaceutical Drugs

New Drugs Division. Frequently Asked Questions (FAQs) on Approval of new Phytopharmaceutical Drugs Central Drugs Standard Control Organization Directorate General of Health Services Ministry of Health and Family Welfare Government of India New Drugs Division Frequently Asked Questions (FAQs) on Approval

More information

NIA Magellan 1 Radiation Oncology Solution Provider Training

NIA Magellan 1 Radiation Oncology Solution Provider Training NIA Magellan 1 Radiation Oncology Solution Provider Training Provider Training Program 1 - NIA Magellan refers to National Imaging Associates, Inc. NIA Magellan Training Program 2 NIA Magellan Program

More information

CHAPTER 7 SECTION 24.1 PHASE I, PHASE II, AND PHASE III CANCER CLINICAL TRIALS TRICARE POLICY MANUAL M, AUGUST 1, 2002 MEDICINE

CHAPTER 7 SECTION 24.1 PHASE I, PHASE II, AND PHASE III CANCER CLINICAL TRIALS TRICARE POLICY MANUAL M, AUGUST 1, 2002 MEDICINE MEDICINE CHAPTER 7 SECTION 24.1 ISSUE DATE: AUTHORITY: 32 CFR 199.4(e)(26) I. DESCRIPTION The Department of Defense (DoD) Cancer Prevention and Treatment Clinical Trials Demonstration was conducted from

More information

Martin Shimer Deputy Director, Division of Legal and Regulatory Support Office of Generic Drug Policy

Martin Shimer Deputy Director, Division of Legal and Regulatory Support Office of Generic Drug Policy M E M O R A N D U M DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH DATE: November 9, 2017 FROM: Martin Shimer Deputy

More information

Appendix C NEWBORN HEARING SCREENING PROJECT

Appendix C NEWBORN HEARING SCREENING PROJECT Appendix C NEWBORN HEARING SCREENING PROJECT I. WEST VIRGINIA STATE LAW All newborns born in the State of West Virginia must be screened for hearing impairment as required in WV Code 16-22A and 16-1-7,

More information

Master Files with ectd

Master Files with ectd Master Files with ectd Follow-up Information Meeting Step 2 Dr. Christoph Berger August 31, 2010 Swissmedic Schweizerisches Heilmittelinstitut Hallerstrasse 7 CH-3000 Bern www.swissmedic.ch Overview 1.

More information

in the ICH Regions Table of Content Annexes to Guideline and 3. Why is Q4B necessary? Q4B Annexes? for Human Use

in the ICH Regions Table of Content Annexes to Guideline and 3. Why is Q4B necessary? Q4B Annexes? for Human Use Frequently Asked Questions Q4B: Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions The Q4B Expert Working Group developed a set of frequently asked questions to help users

More information

My VeriSTAR & Veristar Info: The all-in-one portal for Marine professionals

My VeriSTAR & Veristar Info: The all-in-one portal for Marine professionals My VeriSTAR & Veristar Info: The all-in-one portal for Marine professionals My VeriSTAR mobile application Veristar Info website Monitor your fleet Plan your surveys Stay informed, anytime, anywhere Manage

More information

CERTIFICATION IN LOWER EXTREMITY GERIATRIC MEDICINE CASE REQUIREMENTS AND GUIDELINES

CERTIFICATION IN LOWER EXTREMITY GERIATRIC MEDICINE CASE REQUIREMENTS AND GUIDELINES CERTIFICATION IN LOWER EXTREMITY GERIATRIC MEDICINE CASE REQUIREMENTS AND GUIDELINES 555 8 th Ave Suite 1902 New York, NY 10018 (888) 852-1442 Document number: 61714.10142017 Originated 10.14.2017 ABMSP

More information

Practical guidance for applicants on the submission of applications on food additives, food enzymes and food flavourings

Practical guidance for applicants on the submission of applications on food additives, food enzymes and food flavourings Version 2 Updated on 29/11/2011 Practical guidance for applicants on the submission of applications on food additives, food enzymes and food flavourings Valid as of: 11 September 2011 Disclaimer: This

More information

REGULATORY REQUIREMENTS FOR REGISTRATION OF HEALTH SUPPLEMENTS IN MALAYSIA

REGULATORY REQUIREMENTS FOR REGISTRATION OF HEALTH SUPPLEMENTS IN MALAYSIA REGULATORY REQUIREMENTS FOR REGISTRATION OF HEALTH SUPPLEMENTS IN MALAYSIA TAN JAS MIN National Pharmaceutical Regulatory Agency Ministry of Health Malaysia Email address: tanjasmin@npra.gov.my ORGANISATION

More information

RAPID Meeting. February 2018

RAPID Meeting. February 2018 RAPID Meeting February 2018 Agenda 2017 Annual Inspection Results and 2018 Priorities InfoEd Updates Refrigerator and Freezer Monitoring Program Lessons Learned Program New EHS Customer Satisfaction Survey

More information

Camp SOCIAL Malden Higher Education Center 700 N. Douglass Street Malden, MO Camp Tuition: PAID by SE PAC* Ages Divided in Groups

Camp SOCIAL Malden Higher Education Center 700 N. Douglass Street Malden, MO Camp Tuition: PAID by SE PAC* Ages Divided in Groups A Social Cognition Camp for Youth with HFA Sponsored by Southeast Missouri Autism Project Parent Advisory Committee SESSION 1 Dates: June 6-10, 2016 Monday through Friday 8:30 am to Noon All Camp Activities

More information

Frequently Asked Questions

Frequently Asked Questions Frequently Asked Questions These were updated on March 2018. 1. Details of revised Scheme from 4 April 2018 We are retaining the higher level of award ( 1,000) for childminders who care for children with

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Burzynski Research Institute

More information

SIS Solution Update. Thierry Cerpolet Senior Manager, Business Solutions and Systems Development IATA. Agenda

SIS Solution Update. Thierry Cerpolet Senior Manager, Business Solutions and Systems Development IATA. Agenda SIS Solution Update Thierry Cerpolet Senior Manager, Business Solutions and Systems Development IATA WFS 2017 Industry Meetings SIS Usage and Performance SIS Major Releases Evolution SIS Infrastructure

More information

UNIT MITIGATION REQUEST FOR CONSIDERATION PROCESS

UNIT MITIGATION REQUEST FOR CONSIDERATION PROCESS What is a mitigating factor? A mitigating factor is a significant occurrence beyond a unit s control that triggers a measurable impact not only on the NPA composite summary, but on the Pay for Performance

More information

HOSPICE INFORMATION FOR MEDICARE PART D PLANS

HOSPICE INFORMATION FOR MEDICARE PART D PLANS HOSPICE INFORMATION FOR MEDICARE PART D PLANS SECTION I -HOSPICE INFORMATION TO OVERRIDE AN HOSPICE A3 REJECT OR TO UPDATE HOSPICE STATUS A. Purpose of the form (please check all appropriate boxes) : Admission

More information

CONSOLIDATED EDISON COMPANY OF NEW YORK, INC. 4 IRVING PLACE NEW YORK, NY 10003

CONSOLIDATED EDISON COMPANY OF NEW YORK, INC. 4 IRVING PLACE NEW YORK, NY 10003 CONSOLIDATED EDISON COMPANY OF NEW YORK, INC. 4 IRVING PLACE NEW YORK, NY 003 ENERGY EFFICIENCY AND DEMAND MANAGEMENT DEPARTMENT COMMERCIAL CUSTOMER SOLUTIONS SECTION SPECIFICATION EE-CS- REVISION 00 EFFECTIVE

More information

Results from the NAQC annual survey of quitlines, FY17

Results from the NAQC annual survey of quitlines, FY17 Results from the NAQC annual survey of quitlines, FY17 We will start at 3:00pm ET To mute your line: *1 To unmute your line: *1 For operator assistance: *0 Please do not put your line on hold Results from

More information

URGENT MEDICAL DEVICE CORRECTION. Important Information about Animas 2020, IR 1250 or IR 1200 Insulin Pumps

URGENT MEDICAL DEVICE CORRECTION. Important Information about Animas 2020, IR 1250 or IR 1200 Insulin Pumps URGENT MEDICAL DEVICE CORRECTION May 26, 2015 Important Information about Animas 2020, IR 1250 or IR 1200 Insulin Pumps Dear Healthcare Professional: At Animas, we hold our products to the highest standards

More information

Outpatient Quality Reporting Program

Outpatient Quality Reporting Program Abstraction Tricks and Tips Questions & Answers Moderator: Nina Rose, MA Project Coordinator/HSAG Speaker(s): Karen VanBourgondien, RN, BSN Education Coordinator/HSAG June 17, 2015 10:00 a.m. Question

More information

American Emu Association. Certified Emu Oil Program

American Emu Association. Certified Emu Oil Program Table of Contents Part 1. Frequently Asked Questions... 3 Part 2. AEA Certified Fully Refined Seal & Verbiage Usage Requirements... 5 Section A. Program Requirements... 5 Section B. Product Labeling Requirements...

More information

News & Views. Antipsychotics on Maryland Medicaid PDL and Coverage of a 30-day Emergency Supply of Atypical Antipsychotics

News & Views. Antipsychotics on Maryland Medicaid PDL and Coverage of a 30-day Emergency Supply of Atypical Antipsychotics Maryland Medicaid Pharmacy Program News & Views February 2011 Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy Antipsychotics on Maryland Medicaid PDL and Coverage

More information

NYS Paid Family Leave (PFL) Q & A 5/10/18

NYS Paid Family Leave (PFL) Q & A 5/10/18 NYS Paid Family Leave (PFL) Q & A 5/10/18 Question 1: Question 2: What is NYS Paid Family Leave (PFL)? NYS Paid Family Leave will provide eligible workers with wage replacement during time away from work

More information

International Emergency and Expatriate Dental Program Instructions For Dentists

International Emergency and Expatriate Dental Program Instructions For Dentists International Emergency and Expatriate Dental Program Instructions For Dentists DeCare Dental is a leading dental benefit management company, serving a variety of dental benefit brand names across the

More information

4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP

4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP New Mexico s Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy New Mexico and the PMP In 2012, New Mexico had the 3 nd Highest Overdose Death Rate in Nation.! 492 Deaths or a rate of 23.6

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Page 1 of 6 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations P.A. Benjamin Manufacturing

More information

An Epic Battle Pharmacist Heroes vs. Shortages

An Epic Battle Pharmacist Heroes vs. Shortages An Epic Battle Pharmacist Heroes vs. Shortages Erin R. Fox, PharmD, BCPS, FASHP Twitter: @foxerinr mmpharmd Disclosure This presentation represents my own opinions. University of Utah Drug Information

More information

Important Information about your 2.0 ml Animas Insulin Pump Cartridges

Important Information about your 2.0 ml Animas Insulin Pump Cartridges URGENT: INSULIN PUMP 2.0 ml CARTRIDGE RECALL February 24, 2011 Dear Animas Pumper: Important Information about your 2.0 ml Animas Insulin Pump Cartridges Animas Corporation is dedicated to supporting pumpers

More information

Analysis of State Medicaid Agency Performance in Relation to Incentivizing the Provision of H1N1 Immunizations to Eligible Populations

Analysis of State Medicaid Agency Performance in Relation to Incentivizing the Provision of H1N1 Immunizations to Eligible Populations Analysis of State Medicaid Agency Performance in Relation to Incentivizing the Provision of H1N1 Immunizations to Eligible Populations Nancy Lopez, JD, MPH, Ross Margulies, JD/MPH [Cand.], and Sara Rosenbaum,

More information

EHR Developer Code of Conduct Frequently Asked Questions

EHR Developer Code of Conduct Frequently Asked Questions EHR Developer Code of Conduct Frequently Asked Questions General What is the purpose of the EHR Developer Code of Conduct? EHR Association (the Association) members have a long tradition of working with

More information

Dry Needling (DN) Registration

Dry Needling (DN) Registration Dry Needling (DN) Registration To register for any of our programs, please complete the enclosed registration form (next page) and mail of fax the form to us. Fees Cost of the DN 1-3 courses is US $895

More information

State of Connecticut Department of Education Division of Teaching and Learning Programs and Services Bureau of Special Education

State of Connecticut Department of Education Division of Teaching and Learning Programs and Services Bureau of Special Education State of Connecticut Department of Education Division of Teaching and Learning Programs and Services Bureau of Special Education Introduction Steps to Protect a Child s Right to Special Education: Procedural

More information

Guidance on Drug Master File System in Japan

Guidance on Drug Master File System in Japan 2 nd China Japan Symposium on Drug Development focusing on IND, Pre Consultation, ti GMP and DMF System March 29, 2011 in Beijing Guidance on Drug Master File System in Japan Takashi YOSHITANI, Ph.D. Master

More information

Chapter 18 Section 2. EXPIRED - Department Of Defense (DoD) Cancer Prevention And Treatment Clinical Trials Demonstration

Chapter 18 Section 2. EXPIRED - Department Of Defense (DoD) Cancer Prevention And Treatment Clinical Trials Demonstration s And Pilot Projects Chapter 18 Section 2 EXPIRED - Department Of Defense (DoD) Cancer Prevention And Treatment Clinical Trials 1.0 PURPOSE The purpose of this demonstration is to improve TRICARE-eligible

More information

Frequently Asked Questions

Frequently Asked Questions Frequently Asked Questions (Updated November 2018.) The Department for Education has taken the decision to end the Childcare Business Grant Scheme (CBGS) from 31 March 2019. This is based largely on a

More information

Professional CGM Reimbursement Guide

Professional CGM Reimbursement Guide Professional CGM Reimbursement Guide 2015 TABLE OF CONTENTS Coding, Coverage and Payment...2 Coding and Billing...2 CPT Code 95250...3 CPT Code 95251...3 Incident to Billing for Physicians..............................................

More information

Certified Peer Specialist Training Application

Certified Peer Specialist Training Application Please read the CPS Application Supplement before completing application. Go to http://www.viahope.org/resources/peer-specialist-training-application-supplement This training is intended for individuals

More information

What's Important to Consider When Developing a Complex Generic Drug? September 5, 2018

What's Important to Consider When Developing a Complex Generic Drug? September 5, 2018 What's Important to Consider When Developing a Complex Generic Drug? September 5, 2018 Session Description FDA has provided drug manufacturers tools to assist the development of complex generic drugs to

More information

Primer: Medical Device User Fee Amendments Han Zhong l September 2011

Primer: Medical Device User Fee Amendments Han Zhong l September 2011 Primer: Medical Device User Fee Amendments Han Zhong l September 2011 Introduction The Medical Device User Fee and Modernization Act (MDUFMA or MDUFA) is a set of agreements between the Food and Drug Administration

More information

Lactose, Monohydrate

Lactose, Monohydrate Lactose, Monohydrate Product Regulatory Data Sheet Section 1 Product Information Products Covered Brand Product Code Product Description MOC Code J.T.Baker 2249 Lactose, Monohydrate, Powder N.F. R J.T.Baker

More information

FREQUENTLY ASKED QUESTIONS

FREQUENTLY ASKED QUESTIONS FREQUENTLY ASKED QUESTIONS Since the implementation of the Safe and Sacred program, the Office of Safe Environment Programs has received some questions from our users about the program and the background

More information

Fertility Center and Sperm Bank Manual for the Fertile Hope Program for Men

Fertility Center and Sperm Bank Manual for the Fertile Hope Program for Men Fertility Center and Sperm Bank Manual for the Fertile Hope Program for Men Table of Contents I. Fertile Hope Program for Men: An Overview...3 II. Referring to the Fertile Hope Program in Your Publications.3

More information

Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation

Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation Guidance for Industry U.S. Department of Health and Human Services

More information